Ovarian Cancer Clinical Trials in Boston

Showing 1-20 of 191 trials

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)

NCT03393884

This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus NACT compared to NACT alone.

Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer

Imunon130 participantsStarted Sep 2018

Birmingham, Alabama, United States • Mobile, Alabama, United States • Newport Beach, California, United States +18 more locations

RECRUITINGPhase 1< 1 mile

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

NCT06997029

The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.

Advanced Solid TumorAdvanced Breast CancerAdvanced Ovarian Cancer

Bristol-Myers Squibb234 participantsStarted Aug 2025

Birmingham, Alabama, United States • Fullerton, California, United States • Greenbrae, California, United States +18 more locations

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

Ovarian Cancer Trials in Other Cities

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

PF-07104091 as a Single Agent and in Combination Therapy

REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

GEN1047 for Solid Tumors - First in Human (FIH) Trial

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Other Conditions in Boston